Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Apply
Frexalimab, SAR442970, Rilzabrutinib
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step